Second, the study included cases that occurred before 2016, where the glioma subtype classification at that time was different from the recent 2016 WHO criteria, causing half of those cases to lack evidence of subdivision (for instance, isocitrate dehydrogenase (IDH)) for the latter classification criteria. This evidence concerns the gene IDH3A and central nervous system cancer.